CSF-tau protein: sensitivity and specificity for Alzheimer’s disease
| Groups | No | Mean (pg/ml) | Cut off (pg/ml) | Sensitivity (%) | Specificity (%) | Method | Study |
|---|---|---|---|---|---|---|---|
| AD | 37 | 407 (241) | 59 | Athena | Motter et al 9 | ||
| Healthcontrols | 20 | 212 (102) | 312 | 95 | |||
| Other neurological disorder | 32 | 168 (63) | 97 | ||||
| AD | 71 | 361 (166) | 39 | Athena | Vigo Pelfrey et al 10 | ||
| Neurological controls | 59 | 190 (80) | 400 | 100 | |||
| Non-AD dementia | 25 | 235 (104) | 96 | ||||
| Other neurological disorder | 26 | 193 (127) | 88 | ||||
| AD (mildly demented) | 36 | 509 (255) | 81 | Athena | Galasko et al 19 | ||
| Healthy controls | 14 | 177 (82) | 312.00 | NG | |||
| Non-AD dementia | 9 | 166 (43) | NG | ||||
| Other neurological disorder | 10 | 160 (69) | NG | ||||
| AD | 24 | 1430 (739) | ∼1300 | 46 | Munroe et al 15(Athena antibodies) | Munroe et al 15 | |
| Healthy controls | 14 | 816 (355) | 79 | ||||
| Neurological controls | 26 | 790 (579) | 92 | ||||
| Other neurological disorder | 13 | 810 (441) | 85 | ||||
| AD | 27 | 10.9 (4.9) | 81 | Innogenetics (AT120 + Polycl) | Vandermeerenet al 5 | ||
| Healthy controls | 51 | 0.1 (0.55) | 1.1 | 96 | |||
| Other neurological disorder | 129 | 3.9 (7.4) | 64 | ||||
| AD | 69 | 77.2 (45.5) | 99 | Innogenetics (1st generation) | Araiet al 6 | ||
| Healthy controls | 19 | 9.0 (4.5) | 22.6 | 100 | |||
| Parkinson’s disease | 7 | 15.6 (7.7) | 86 | ||||
| ALS | 4 | 18.2 (10.1) | 75 | ||||
| Cerebrovascular disorder | 19 | 23.4 (33.1) | 84 | ||||
| AIDS | 4 | 49.6 (37.6) | 25 | ||||
| Meningoencephalitis | 35 | 30.1 (43.4) | ∼60 | ||||
| Epilepsy | 6 | 14.2 (10.6) | 83 | ||||
| Other neurological disorder | 21 | 32.8 (49.2) | ∼67 | ||||
| AD | 19 | 70 (8) | NG | NG | Innogenetics (1st generation) | Hocket al 16 | |
| Neurological controls | 18 | 27 (4) | NG | ||||
| AD | 23 | 279 (100) | NG | Innogenetics | Tato et al 11 | ||
| Neurological controls | 23 | 26 (11) | NG | ||||
| MID (DSM-III-R) | 36 | 88 (61) | NG | ||||
| Familial AD | 8 | 346 (136) | 100 | Innogenetics (tau/g protein) | Jensen et al 8 | ||
| Sporadic AD | 7 | 370 (129) | 95 | ||||
| Neurological controls | 22 | 51 (26) | 180 | 93 | |||
| Other neurological disorder | 31 | 155 (146) | 87 | ||||
| AD | 44 | 540 (280) | 84 | Innogenetics (2nd generation) | Blennowet al 7 | ||
| Healthy controls | 31 | 185 (50) | 258 | 97 | |||
| VAD (NINDS-AIREN) | 17 | 445 (195) | 24 | ||||
| Frontal lobe dementia | 11 | 275 (131) | 64 | ||||
| Parkinson’s disease | 15 | 216 (105) | 73 | ||||
| Depression | 10 | 108 (13) | 100 | ||||
| AD | 11 | 254 (113) | NG | Innogenetics (2nd generation) | Skooget al 13 (population based study of 85 year olds) | ||
| Non-demented | 35 | 171 (78) | |||||
| VAD (NINDS-AIREN) | 13 | 247 (75) | NG | ||||
| AD (mildly demented) | 22 | 565 (median) | NG | NG | Innogenetics (2nd generation) | Riemenschneider et al 17 | |
| Healthy controls | 19 | 160 (median) | NG | NG | |||
| AD | 16 | ∼325 (mean) | 225 | 88 | Innogenetics (2nd generation) | Rosleret al 18 | |
| Neurological controls | 10 | ∼125 (mean) | 100 | ||||
| Depression | 11 | ∼150 (mean) | 91 | ||||
| Other neurological disorder | 20 | ∼200 (mean) | 80 | ||||
| AD | 14 | 820 (90) | 100 | Mori et al 12 | Moriet al 12 | ||
| Healthy controls | 36 | 380 (120) | ∼600 | 94 | |||
| Cerebrovascular disorder | 12 | ∼4-500 | 100 |
AD = Alzheimer’s disease; ALS = amyotrophic lateral sclerosis; AIDS = acquired immunodeficiency syndrome; MID = multi-infarct dementia; VAD = vascular dementia; NG = not given.
Healthy controls = people without symptoms or signs of brain disorders, including cognitive symptoms. Neurological controls = patients with minor neurological or psychiatric disorders (for example, headache, depression). Other neurological disorders = for example, multiple sclerosis, stroke, ALS, inflammatory disorders, hydrocephalus. In the 1st generation of the innogenetics assay, a technical error in the determination of the tau standard gave rise to 6.9 times falsely low CSF-tau values.